Treatment Access News
Nova Scotia Lists EPCLUSA™ on Public Drug Plan to Treat All Six Genotypes of Chronic Hepatitis C Infection
may 1, 2017
Gilead Sciences Canada, Inc. (Gilead Canada) today announced, effective immediately, Nova Scotia will provide public access to EPCLUSA™ (sofosbuvir/velpatasvir) tablets, the first once-daily, pan-genotypic single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. This listing will support patients to access curative therapy, and will advance Canada's efforts to achieving its World Health Organization commitment to eliminate hepatitis C by 2030.